MétaCan
Menu
← Back to cohort

A phase III randomized controlled trial comparing palliative stereotactic body radiotherapy vs. palliative standard radiotherapy in patients with advanced head and neck cancer (NCT06641791).

2025· article· en· W4410795548 on OpenAlexafffund
Ian Poon, Irene Karam, Houda Bahig, Brock Debenham, Adam Mutsaers, Murali Rajaraman, C. Jillian Tsai, Chin Lee, Madette Galapin, Scott V. Bratman, Jolie Ringash, Ambika Parmar, Koren Smith, Sarah Radcliffe, Wei Tu, Wendy R. Parulekar

Bibliographic record

VenueJournal of Clinical Oncology · 2025
Typearticle
Languageen
FieldMedicine
TopicHead and Neck Cancer Studies
Canadian institutionsUniversity of TorontoUniversity Health NetworkPrincess Margaret Cancer CentreNova Scotia Cancer CentreQueen's UniversityLondon Health Sciences CentreUniversity of AlbertaCentre Hospitalier de l’Université de MontréalHealth Sciences CentreWestern UniversitySunnybrook Health Science Centre
FundersCanadian Institutes of Health Research
KeywordsMedicineRadiation therapyHead and neck cancerHead and neckRadiosurgeryRandomized controlled trialPalliative treatmentPalliative careRadiologyNuclear medicineSurgery

Abstract

fetched live from OpenAlex

TPS6118 Background: The optimal radiotherapy (RT) treatment regimen for patients with advanced head and neck cancer (AHNC) unsuitable to receive curative intent RT is undefined. Stereotactic body radiotherapy (SBRT) is a promising technique but rigorous multicentre evaluation is required prior to adoption. Methods: This is a Phase III randomized controlled trial comparing palliative SBRT to palliative standard RT (SRT) in participants with advanced mucosal, squamous cell head and neck cancer unable to tolerate curative intent RT. Key eligibility criteria: Unsuitable for curative intent therapy, no evidence of metastatic disease, stages TX or T0-T4/N0-N3, geriatric 8 score [1] ≤14. Treatment arms: (Experimental) SBRT 4500 cGy/ 5fr (twice a week to primary and nodal GTV (BED 10 85) OR 4000 cGy /5 fr twice a week if organs at risk (BED 10 -72) versus (standard) 2400 cGy/ 3fr (day 0/7/21 (BED 10 43) or 2500 cGy/ 5fr over 1 week (BED 10 38). Primary objective: To compare OS between arms. Secondary objectives evaluate progression-free survival (PFS), locoregional failure-free survival, distant metastases-free survival, response rates, acute and long-term toxicity (CTCAE v5.0), treatment compliance, patient-reported outcomes (PRO-CTCAE, FACT-HN), resource utilization, and health utilities. Statistical design : The trial aims to enroll 196 patients with a 2:1 randomization ratio (SBRT:SRT). The study is powered at 80% with a two-sided alpha of 0.05 to detect a difference in 1-year OS of 40.3% vs. 22% (HR = 0.6), assuming a 15% drop-out/lost to follow-up rate. Conduct to Date : This trial was activated on October 31, 2024. Supported by CCS grant #707213; CIHR #175014. [1] Takahashi M, Takahashi M, Komine K, Yamada H, Kasahara Y, Chikamatsu S, et al. (2017) The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study. PLoS ONE 12(6): e0179694. https://doi.org/10.1371/journal.pone.0179694. Clinical trial information: NCT06641791 .

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.004
metaresearch head score (Gemma)0.005
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: Randomized trial
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.029
Threshold uncertainty score0.098

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0040.005
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0040.003
Bibliometrics0.0010.001
Science and technology studies0.0010.001
Scholarly communication0.0010.001
Open science0.0020.001
Research integrity0.0020.004
Insufficient payload (model declined to judge)0.0290.003

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.054
GPT teacher head0.480
Teacher spread0.426 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicHead and Neck Cancer Studies→French-language works237,207→